Get the Daily Brief
Latest Biotech News
Tiprelestat shows benefit in hospitalized COVID‑19 – COMCOVID randomized trial
The double‑blind, randomized, placebo‑controlled COMCOVID trial reported that Tiprelestat produced clinically meaningful improvements in hospitalized COVID‑19 patients. The study assessed...
First circRNA‑based protein replacement reverses liver fibrosis in preclinical tests
Researchers in China described a circular RNA (circRNA) therapeutic encoding human relaxin‑2 (cRLN2) as a first‑of‑its‑kind circRNA protein‑replacement strategy for liver fibrosis. The authors...
Agomab, SpyGlass file IPO plans as biotech window reopens
Immunology biotech Agomab Therapeutics and ocular specialist SpyGlass Pharma announced intentions to pursue initial public offerings, signaling renewed IPO activity in biotech. Both companies...
Engineered bacteria glue seals gut bleeds — durable mucosal repair in mice
Researchers engineered nonpathogenic Escherichia coli with a blood‑inducible circuit that secretes a barnacle-derived adhesive (CP43K) and the mucosal‑healing factor TFF3, enabling bacteria to...
FDA clears IND for D3 Bio KRAS G12D inhibitor — first‑in‑human trial next
D3 Bio announced FDA IND clearance for D3S‑003, its KRAS G12D selective inhibitor, enabling a first‑in‑human Phase I study in patients with advanced solid tumors harboring KRAS G12D mutations. The...
AstraZeneca buys remaining China rights to armored CAR‑T — deal worth up to $630M
AstraZeneca agreed to pay up to $630 million to acquire the remaining China rights to C‑CAR031, an armored GPC3‑targeting CAR‑T developed with AbelZeta Pharma, giving AstraZeneca full global...
AI builds bacteriophages from scratch — researchers flag opportunities and risks
Teams reported AI models capable of designing complete bacteriophage genomes de novo, enabling rapid in‑silico construction of phage candidates. The work, covered by BioTecNika, demonstrates how...
FDA turmoil overshadows 2025 approvals — pipeline produced more follow‑ons than first‑in‑class
Nature Biotechnology reported that 2025 at the FDA was marked by leadership turnover, staff reductions and policy shifts that reshaped the agency’s review environment while new drug approvals...
Engineered UGA‑suppressor tRNA expands AAV delivery window — disease‑agnostic approach
A Nature Biotechnology paper described an engineered UGA suppressor tRNA gene designed for AAV delivery that enables readthrough of UGA stop codons in vivo, broadening the class of genetic lesions...
CircRNA protein replacement: first preclinical candidate reverses liver fibrosis
Researchers in Shanghai described a circular RNA (circRNA) encoding human relaxin‑2 (cRLN2) as a protein‑replacement therapeutic for liver fibrosis. The circRNA approach leverages inherent...
Unedited CD7 CAR‑T exploits fratricide to target T‑cell leukemia
A Journal of Translational Medicine study reported that fratricide‑driven, unedited CD7 CAR‑T cells show therapeutic promise against T‑cell leukemia, leveraging the natural elimination of...
Novel nOPV2 shows higher genetic stability amid neurovirulent poliovirus strains
Researchers reported that a next‑generation live attenuated oral poliovirus type 2 vaccine (nOPV2) exhibits improved genetic stability compared with earlier strains when challenged by...
AI in biology: generative agents and probes speed discovery — from targets to live‑cell imaging
Two reports highlight AI’s expanding role across biotech workflows. A broad piece argued that AI agents are being deployed across drug discovery tasks—target identification, design and candidate...
Living bacterial glue targets bleeding... a new IBD therapy
Researchers engineered nonpathogenic Escherichia coli to detect gastrointestinal bleeding and secrete both a barnacle-derived adhesive protein (CP43K) and the mucosal-repair factor TFF3, enabling...
FDA under strain: approvals, leadership and legal questions
Nature Biotechnology reports leadership turnover, staff cuts and new policies that reshaped the FDA’s 2025 approvals landscape, producing more follow-on products than first-in-class drugs....
AI-built phages raise biosecurity alarms
Researchers and commentators reported that AI models can now design complete bacteriophage genomes from scratch, enabling de novo phage generation. The development—covered by industry...
tRNA trick: disease-agnostic AAV delivery
A study published in Nature Biotechnology describes an engineered UGA‑suppressor tRNA gene designed to broaden the targets addressable by AAV-delivered therapies. The suppressor tRNA enables...
Sarepta sales miss rekindles gene‑therapy safety debate
Sarepta reported preliminary Q4 2025 results that missed analyst forecasts for Elevidys, the only FDA‑approved gene therapy for Duchenne muscular dystrophy, and shares tumbled about 11% after the...
Unedited CD7 CAR‑T shows promise in T‑cell leukemia
A Journal of Translational Medicine study reported that fratricide-driven, unedited CD7 CAR‑T cells can target T‑cell leukemia effectively without extensive gene editing to remove CD7, leveraging...
Two‑step genome editing creates full‑length humanized mice
Researchers described a two‑step genome‑editing strategy that enables replacement of entire mouse loci with full‑length human sequences, producing humanized mouse models that retain native...